The FDA’s accelerated approval program is meant to give patients early access to promising drugs, but a new study found most cancer drugs do not demonstrate benefits within five years.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec.